Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study

MLA

van Oosterom, Allan T., et al. “Safety and Efficacy of Imatinib (STI571) in Metastatic Gastrointestinal Stromal Tumours: A Phase I Study.” The Lancet, vol. 358, no. 9291, Oct. 2001, p. 1421. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.79556709&authtype=sso&custid=ns315887.

APA

van Oosterom, A. T., Judson, I., Verweij, J., Stroobants, S., di Paola, E. D., Dimitrijevic, S., Martens, M., Webb, A., Sciot, R., Van Glabbeke, M., Silberman, S., & Nielsen, O. S. (2001). Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. The Lancet, 358(9291), 1421.

Chicago

van Oosterom, Allan T, Ian Judson, Jaap Verweij, Sigrid Stroobants, Eugenio Donato di Paola, Sasa Dimitrijevic, Marc Martens, et al. 2001. “Safety and Efficacy of Imatinib (STI571) in Metastatic Gastrointestinal Stromal Tumours: A Phase I Study.” The Lancet 358 (9291): 1421. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.79556709&authtype=sso&custid=ns315887.